KEYTRUDA’s recent success in triple-negative breast cancer validates I-SPY 2 adaptive platform approach to phase II clinical trials

Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity & differential therapeutic responses

AI reveals new breast cancer types that respond differently to treatment

Could a form of cell death enhance cancer immunotherapy?

July 29, 2019 0

Hollings clinical scholar researches novel triple-negative breast cancer treatments

Predicting breast cancer response with ‘high’ TMB

Breast cancer experts highlight key takeaways from the 2019 ASCO annual meeting

NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance

July 19, 2019 0

First positive results reported in TAPUR™ study cohorts